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Abstract  
Glial cell line-derived neurotrophic factor (GDNF) has shown promise in the treatment 
of neurodegenerative disorders of basal ganglia origin such us Parkinson’s disease (PD). 
In this study, we investigated the neurorestorative effect of controlled GDNF delivery 
using biodegradable microspheres in an animal model with partial dopaminergic lesion. 
Microspheres were loaded with N-glycosylated recombinant GDNF and prepared using 
the Total Recirculation One-Machine System (TROMS). GDNF-loaded microparticles 
were unilaterally injected into the rat striatum by stereotaxic surgery two weeks after a 
unilateral partial 6-OHDA nigrostriatal lesion. Animals were tested for amphetamine-
induced rotational asymmetry at different times and were sacrificed two months after 
microsphere implantation for immunohistochemical analysis. The putative presence of 
serum IgG antibodies against rat glycosylated GDNF was analyzed for addressing 
safety issues. The results demonstrated that GDNF-loaded microspheres, improved the 
rotational behavior induced by amphetamine of the GDNF-treated animals together with 
an increase in the density of TH positive fibers at the striatal level. The developed 
GDNF-loaded microparticles proved to be suitable to release biologically active GDNF 
over up to 5 weeks in vivo. Furthermore, none of the animals developed antibodies 
against GDNF demonstrating the safety of glycosylated GDNF use.  
 
Key words: GDNF, PLGA microparticles, TROMS, serum IgG antibodies against 
GDNF, Parkinson´s disease. 
 
1. Introduction 
Neurotrophic factors have emerged as promising tools for the treatment of a wide 
variety of neurodegenerative diseases. Among them, the glial cell-line derived 
neurotrophic factor (GDNF) was selected as the most suitable candidate for the 
treatment of Parkinson´s disease (PD) due to its strong trophic effect on the 
dopaminergic system [1, 2]. The initial successful results obtained in relevant animal 
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models of the disease led to different clinical trials in PD patients. The outcome 
obtained in two independent Phase I clinical trials known as the “Bristol” and 
“Kentucky” studies [3-5], using direct intraputaminal infusion of naked nonglycosylated 
GDNF through mini-pumps, was not further confirmed by a double-blind Phase II study 
using a similar strategy [6]. Several safety concerns were reported, such as the 
appearance of blocking antibodies against GDNF, together with the presence of 
unexpected cerebellar damage in a toxicology study carried out in parallel in primates 
treated with high doses of GDNF. However, the main reason for the discontinuation of 
the study was the failure of reaching the primary endpoint [6]. Differences in GDNF 
doses, catheter size and infusion methods may have resulted in different GDNF spread 
and bioavailability. Recently, the statistical design of this Phase II study was also 
questioned [7]. 
Several strategies have been used for GDNF release in the central nervous system 
(CNS). A catheter connected to an infusion pump has already been used in PD patients 
[3-6]. This method has some disadvantages, such as the need of high concentrations of 
the neurotrophic factor as well as pump refilling, together with limited tissue diffusion 
of the delivered protein [8]. Another feasible option is the use of gene therapy using 
different strains of modified viruses carrying the GDNF gene [9-11]. This approach also 
presents some disadvantages such as the lack of control of the duration of the transgene 
expression, the viral spread outside the target area, and the difficulties in calculating the 
exact amount of GDNF produced from the viral-infected neurons. Finally, a different 
alternative would be the use of cell therapy strategies using cells genetically engineered 
to release GDNF [12]. However, several concerns have been raised, related to the 
reduced rate of cellular survival within the implanted graft, as well as the presence of 
immune rejection of the grafted cells by the host tissue.  
When compared to the existing strategies, the use of biodegradable and biocompatible 
microspheres for the controlled brain release of GDNF could represent an attractive 
alternative for several reasons. First of all, microparticles are prepared with 
biodegradable polymers that do not require removal once the treatment is finished. 
Secondly, brain biocompatibility of particles prepared with poly (lactic-co-glycolic) 
acid (PLGA) polymers has already been well established [13-16] and therefore the 
appearance of host immune reaction against injected microparticles is very unlikely. 
Finally, the drug release profile of PLGA microspheres brings another important 
advantage. Therefore, GDNF dosage could be diminished, leading to a reduction of the 
possible side effects. However, protein encapsulation is not an easy task due to the 
labile nature of these macromolecules. Among the methods described, multiple 
emulsion solvent evaporation technique (W/O/W) is generally accepted as the most 
suitable to encapsulate proteins and peptides [17]. Nevertheless, proteins may lose their 
biological activity during the manufacturing process. Since shear stress and vortexing 
are avoided, multiple emulsion prepared by Total Recirculation One-Machine System 
(TROMS) may be a feasible way of overcoming protein denaturation during 
microparticle preparation [18]. TROMS technology also produces very homogeneous 
batches on a semi-industrial scale, which is of great interest considering future scaling-
up and industrial issues. 
Different formulations loaded with glycosylated rat recombinant GDNF were 
previously analyzed to optimize the neurotrophic factor microencapsulation by TROMS 
technology, the stability of the protein during the manufacturing process and the drug 
release profile [19]. In the present work we move one step forward by testing the in vivo 
efficacy and safety of GDNF-loaded microspheres in a rodent model of PD. We are 
particularly interested in evaluating their ability to restore the dopaminergic innervation 
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in a model of partial dopaminergic fiber depletion that mimics the situation encountered 
in PD patients. Rotational testing, histological assessment as well as antibody response 
to glycosylated GDNF were performed to analyze the effects of GDNF-loaded 
microparticles after implantation in parkinsonian rats. 
 
2. Materials and Methods 
2.1 Materials  
Rat recombinant glycosylated GDNF was expressed and purified as previously 
described [20]. Recombinant insect cell-derived rat GDNF was purchased from SIGMA 
(Steinheim, Germany). GDNF enzyme linked immunosorbant assay kit (ELISA) was 
purchased from Promega (Madison, USA). Poly (lactic-co-glycolic) acid (PLGA) with a 
lactic:glycolic ratio of 50:50 RG 503H (MW 34 kDa) was provided by Boehringer-
Ingelheim (Ingelheim, Germany). Dichloromethane, acetone, dimethilsulphoside and 
glycerine were obtained from Panreac Quimica S.A (Barcelona, Spain). Poly (vinyl 
alcohol) 88 % hydrolyzed (MW: ~ 125,000) was obtained from Polyscences, Inc 
(Warington, USA). The rat pheocromocytome PC-12 cells were purchased from 
American Type Culture Collection (ATCC) (Rockville, MD, USA). Normal goat serum, 
normal rabbit serum, biotinylated rabbit anti goat IgG and the Vectastain ABC kit was 
provided by Vector Laboratories (Burlingame, CA, USA). Triton X-100, ExtrAvidin®-
Peroxidase, mouse anti TH monoclonal antibody, 6-hydroxydopamine hydrochloride, 
3,3´-diaminobenzidine, D-amphetamine sulphate, and rhodamin B isothiocyanate were 
from Sigma-Aldrich (Barcelona, Spain). DPX was obtained from BDH Chemicals 
(Poole, UK). H2O2 and paraformaldehyde were purchased from Merck (Barcelona, 
Spain). Carboxymethylcellulose and mannitol were obtained from Cooper 
Pharmaceutique (Melun, France). Polysorbate 80 was provided by Prolabo (Paris, 
France). Biotinylated goat anti mouse IgG was obtained from Jackson ImmunoResearch 
(West Grove, PA, USA). Goat anti GDNF antibody was purchased from R&D systems 
(Minneapolis, MN, USA), rabbit anti GFAP antibody was obtained from DAKO 
(Trappes, France), mouse anti CD11b antibody was purchased from AbD Serotec 
(Oxford, England) and rat anti dopamine transporter monoclonal antibody were 
obtained from Chemicon International (Temecula, CA, USA). Donkey anti rabbit and 
donkey anti mouse coupled to Alexa®488 were from Molecular Probes (Eugene, OR, 
USA). Horseradish-peroxidase–conjugated goat anti-rat IgG, horseradish-peroxidase–
conjugated donkey anti rabbit IgG and horseradish-peroxidase–conjugated sheep anti 
mouse IgG were from Amersham GE Healthcare (Buckinghamshire, UK). o-
phenylenediamine dihydrochloride were obtained from SIGMA (Saint Louis, MO, 
USA). The rabbit anti GDNF polyclonal antibody and the mouse anti GDNF 
monoclonal IgG1 antibody were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA).  
 
2.2 Preparation of GDNF-loaded microspheres 
GDNF-loaded microparticles were prepared by solvent extraction/evaporation method 
using TROMS as previously described [19]. Briefly, the organic solution composed of 2 
ml of dichlorometane:acetone (3:1) containing 100 mg of Resomer RG 503H was 
injected through a needle with an inner gauge diameter of 0.17 mm at a ratio of 30 
mL/min into the inner aqueous phase (200 μl). The inner aqueous phase contained 135 
µg of GDNF in 10 mM phosphate, 50 mM sodium chloride (PBS), pH 7.9, 5 mg of 
HSA and 5 µl of PEG 400. Next, the primary emulsion (W1/O) was recirculated through 
the system for 3 min under a turbulent regime at a flow rate of 30 mL/min. The first 
emulsion was then injected into 30 mL of the external aqueous phase (W2) composed of 
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1.5% PVA. The turbulent injection through the needle with an inner gauge diameter of 
0.50 mm resulted in the formation of a multiple emulsion (W1/O/W2), which was further 
homogenized by circulation through the system for 4 min. The W1/O/W2 emulsion was 
stirred at 1000 rpm at room temperature for at least 3 hours to allow solvent evaporation 
and microspheres formation. Finally, particles were washed with ultrapure water and 
freeze-dried. For fluorescence-labelled microparticles, rhodamin B isothiocyanate (0.5 
mg/mL) was added to inner aqueous phase and microspheres were prepared as 
described above. 
 
2.3 Characterization of microspheres 
2.3.1 Particle size analysis 
The mean particle size and size distribution of the microspheres were examined by laser 
diffractometry using a Mastersizer-S® (Malvern Instruments, Malvern, UK). 
Microspheres were dispersed in ultrapure water and analyzed under continuous stirring. 
The average particle size was expressed as the volume mean diameter in micrometers. 
Samples were read in triplicate. 
 
2.3.2 Particle morphology 
Both the microsphere shape and surface structure were evaluated by SEM using Zeiss 
DSM 940A microscope with a digital imaging capture system (DISS of Point Electronic 
GmbH). 
 
2.3.3 Drug content 
The amount of GDNF encapsulated in the microspheres was determined by dissolving 5 
mg of freeze-dried loaded particles in 1 ml of dimethyl sulfoxide (DMSO). Previously, 
it was verified that DMSO did not affect GDNF stability. The quantity of GDNF was 
measured in triplicates by ELISA using the GDNF Emax® ImmunoAssay System 
according to the manufacturer´s instructions. 
 
2.3.4 In vitro release of GDNF from PLGA microspheres  
GDNF-loaded microspheres (1 mg, n = 3) were resuspended by vortexing in 0.5 ml of 
PBS, pH 7.4 containing 0.1% BSA and 0.02% w/w sodium azide. Incubation took place 
in rotating vials at 37 °C. At defined times ranging from 30 min to 40 days, samples 
were centrifuged at 25000 g, for 15 min. Due to the instability of the protein in the 
release medium, the amount of drug released was indirectly determined by measuring 
the quantity of GDNF remaining within the microspheres by ELISA. Release profiles 
were expressed in terms of cumulative release, and plotted versus time. 
 
2.3.5 In vitro bioactivity assay 
The bioactivity of released GDNF was assessed using the PC-12 cell line as described 
previously [20]. These cells differentiate to a neural phenotype in response to 
neurotrophic factors such as GDNF or NGF [20-21]. PC-12 cells were plated onto 12 
well culture plate at a low density, 2 x 103 cells/cm2 in 1 ml of culture media. The 
culture medium was supplemented 24 hours later with 50 ng of GDNF released from 
microspheres over 24 hours, which had previously been quantified by ELISA. Neurite 
outgrowth was visualized after 7 days in culture under phase contrast illumination with 
a Leika DM IRB inverted microscope connected to a Hamamatsu ORCA-ER digital 
camera. PC-12 cells incubated with 50 ng/ml of purified rat recombinant GDNF were 
used as a positive control of the technique. PC-12 cells incubated with medium 
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supplemented with the released medium from non-loaded microspheres were used as 
negative control of the technique. 
 
2.4 In vivo efficacy of GDNF brain delivery through PLGA microspheres 
A total number of 15 female Sprague–Dawley rats (Harlan, Barcelona, Spain), with a 
body weight between 220 to 240 g at the beginning of the experiment, were used in this 
study. Animals were kept in standard animal facilities with free access to food and 
water, in a temperature and humidity-controlled room with 12 h on–off light cycle. 
Animal handling was conducted at all times in compliance with the regulations of the 
Ethical Committee of the University of Navarra as well as with the European 
Community Council Directive Ref. 86/609/EEC.  
 
2.4.1 6-OHDA lesion surgery  
Animals were deeply anesthetized via an i.p. injection of a 1:1 mixture of ketamine (75 
mg/kg) and xylazine (10 mg/kg). Rats were then placed in a stereotaxic frame (David 
Kopf, Tujunja, CA, USA). A total dose of 20 µg of the neurotoxin 6-hydroxydopamine 
(6-OHDA) dissolved in 10 µl of saline with 0.1% ascorbic acid was injected at two sites 
(equally spaced 1 mm apart; final concentration of 10 µg/5µl each) into the right 
striatum [22]. The injection rate was 1 µl/min and the needle was left in place for an 
additional 5 min before withdrawal. The stereotaxic coordinates used to perform the 6-
OHDA lesion were taken from the atlas of Paxinos and Watson [23]. Coordinates for 
the first injection were 0.5 mm rostral to bregma, -2.5 mm lateral from the midline and -
5 mm ventral from the dura surface, whereas the coordinates for the second injection 
were -0.5 mm rostral to bregma, -4.2 mm lateral from the midline and -5 mm ventral 
from the dura surface.  
 
2.4.2 Microspheres  implantation 
For stereotaxic implantation, freeze-dried microspheres were dispersed in a sterile 
aqueous medium consisting of 0.1% (w/v) carboxymethylcellulose, 0.8% (w/v) 
polysorbate 80 and 0.8% (w/v) mannitol in PBS, pH 7.4, for stereotaxic implantation. 
Surgery was performed 2 weeks after the 6-OHDA lesion under aseptic conditions 
using the same stereotaxic coordinates. All the injections were performed at a flow rate 
of 1 µL/min. The syringe was left in place for 5 additional minutes to avoid the 
suspension to be expelled from the brain. Each rat received a total dose of 2.5 µg of 
GDNF in two implantations, each comprising 1.5 mg of microparticles in 8 µl of 
dispersing medium. Control rats received the same amount of non-loaded microspheres 
and sham-operated animals received 2 injections of 8 µl of dispersing medium. 
 
2.5 Behavioral test; drug induced rotation 
The animal rotational behavior induced after an i.p. injection of 5 mg/ml D-
amphetamine was assessed on a computerized rotometer (Panlab, Barcelona, Spain) 13 
days after 6-OHDA administration and 2, 4, 6, and 8 weeks post- treatments. Left and 
right full-body turns were monitored over a 90 min period. Net rotational asymmetry 
score was calculated by subtracting contralateral turns from ipsilateral turns and was 
expressed as full-body turns per minute in the direction ipsilateral to the lesion.  
 
2.6 Histology 
2.6.1 Tissue processing 
At the end of the experiment animals were anesthetized with an overdose of 10% 
chloral hydrate in distilled water and then perfused transcardially with saline Ringer´s 
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solution followed by 500 ml of cold fixative containing 4% paraformaldehyde in 0.125 
M phosphate buffer (PB) pH 7.4. The brains were removed and post-fixed for an 
additional period of 2 h in the same fixative solution and next transferred into a 
cryoprotective solution containing 20% glycerol and 2% dimethylsulphoxide in 0.125 
M PB pH 7.4. Frozen coronal sections (30 µm thick) were obtained in a sliding 
microtome and collected in cryoprotective solution in 8 series of adjacent sections. 
Sections were stored at -80 ºC until further processing. 
 
2.6.2 Immunohistochemistry 
Immunohistochemistry was performed using antibodies against TH (mouse antiTH 
monoclonal antibody used at 1:2000), GDNF (goat anti GDNF antibody used at 1:100), 
Glial fibrillary acidic protein GFAP (rabbit antiGFAP polyclonal antibody used at 
1:1000) and CD11b (mouse antiCD11b monoclonal antibody used at 1:500). For TH 
and GDNF immunohistochemistry, biotinylated goat anti mouse IgG (used at 1:1200) 
and biotinylated rabbit anti goat IgG (used at 1:1200) were used as secondary antibodies 
respectively. Sections were next incubated in a 1:5000 solution of peroxidase-
conjugated ExtrAvidin® and immunoreactive structures were visualized after incubation 
in 0.005% 3,3´-diaminobenzidine (DAB) and 0.001% H2O2. Sections were dehydrated, 
cleared in xylene, and coverslipped with DPX. For GFAP and CD11b 
immunohistochemistry, sections were incubated with the secondary antibody donkey 
anti rabbit or donkey anti mouse coupled to Alexa®488 respectively (used at 1:250), 
rinsed mounted and dehydrated. 
 
2.7 Fiber density measurements 
The optical densities (OD) of the TH-immunoreactive fibers in the striatum were 
measured using a computerized image analysis system (AnalySIS®) 3.1, Soft Imaging 
Systems) reading optical densities as gray levels. For each animal, the optical density 
was measured at three different rostrocaudal levels along the striatum according to 
Paxinos and Watson: (1) rostral striatum (bregma + 1 mm); (2) medial striatum (bregma 
– 0.5 mm); and (3) caudal striatum (bregma – 1 mm). A rectangle of 410.000 µm2 was 
placed on the most lateral region of the striatum and the OD was measured using an 
image analysis software (AnalySIS®) 3.1, Soft Imaging Systems). Optical density values 
for the striatum on the ipsilateral side were expressed as a percentage of the 
contralateral non-lesioned side. 
 
2.8 Evaluation of serum IgG antibody response against rat glycosylated GDNF 
Blood samples were obtained from the animal at the time of perfusion by heart 
puncture. To separate serum, blood was allowed to clot for 1 hour at 37 °C and 
centrifuged at 3000 x g for 15 min at 20 °C. Serum aliquots were stored at −80 °C. For 
the detection of anti–rat GDNF antibodies, 96-well microtiter plates were coated with 
50 ng/well of recombinant rat GDNF in 50 µL carbonate buffer (0,025 M sodium 
bicarbonate, 0,025 M sodium carbonate) pH 8.2, per well overnight at 4 °C. After 
washing with PBS the wells were blocked with blocking buffer (1% BSA, 0,1% Tween-
20, pH 7.4 in PBS) for 1 hour at room temperature. Plates were incubated with 50 
µL/well of serum samples diluted 1:102 and 1:104 in blocking buffer for 2 hours at room 
temperature. After washing, plates were incubated for 30 minutes at room temperature 
with 50 µL/well of 1:103 horseradish-peroxidase–conjugated goat anti-rat IgG in 
blocking buffer, washed, and visualized by incubating with 100 µL solution o-
phenylenediamine dihydrochloride. Absorbance at 450 nm was measured after 30 
6 
minutes. For each sample duplicate determinations of each sample were performed. 
Background correction was determined for each sample using uncoated wells. 
 
 
2.9 Statistical analysis  
All values were expressed as the mean ± s.e. (standard error). Comparisons between 
groups were carried out using one-way ANOVA with Tukey post hoc analysis with and 
SPSS vs 13.0 software.  
 
3. Results 
3.1 Microspheres characterization 
GDNF-loaded microparticles were successfully prepared by W1/O/W2 
emulsion/extraction process using TROMS technology. The mean particle size 
measured by laser diffractometry was 8.42 ± 0.07 µm, which was totally compatible 
with a stereotaxic injection according with previous studies [13]. The total amount of 
loaded GDNF was 68 µg per 100 mg of polymer, suitable for in vivo studies. The yield 
of the fabrication process was 82%. SEM analysis showed that GDNF-PLGA 
microspheres were spherical in shape and with a smooth surface (Figure 1A). 
 
3.2 In vitro release kinetics  
In vitro release kinetics was performed in PBS (pH 7.4) at 37 ºC for 40 days (Figure 
1B). After an initial burst, a continuous GDNF release was observed from day 1 to 14, 
in which drug diffuses through the polymer. Finally, a second increase in the rate of 
release was observed from day 14 to 40 probably caused by polymer degradation. 
Indeed, 67% of the total GDNF was released within the first 40 days. 
 
3.3 In vitro bioactivity assay 
PC-12 cells derive from a rat pheochromocytome and present an undifferentiated aspect 
when grown in culture. When bioactive GDNF is added to the culture medium, the cells 
differentiate and start to develop a neural phenotype visualized by the presence of 
neuronal-like processes. As shown in Figure 1C, no outgrowth of neurites was observed 
in the cells treated with the release medium from non-loaded microspheres. By contrast, 
50 ng of GDNF released from microspheres were able to differentiate PC-12 cells after 
7 days of treatment showing that the released neurotrophic factor remains biologically 
active after the microencapsulation process (Figure 1D). A similar differentiation was 
observed in cells treated with the same amount of purified rat recombinant GDNF 
(Figure 1E). These results demonstrated that the encapsulated GDNF was biologically 
bioactive. 
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Figure 1: (A) Scanning electron micrographs of representative GDNF-loaded PLGA microparticles 
prepared by TROMS technology. (B) GDNF in vitro release profile from PLGA microspheres (n = 3). 
(C-E) Assessment of the biological activity of GDNF released from microparticles. Phase-contrast 
microscopy of cells that were cultured for 7 days in medium supplemented (C) with the release medium 
of non-loaded microspheres, (D) with GDNF released over 24 hours from loaded microparticles and (E) 
with the same amount of purified rat recombinant GDNF. Note the appearance of neurites both in D also 
in E demonstrating the bioactivity of GDNF released from microspheres. Bar length 100 µm 
 
3.4 In vivo experiments 
3.4.1. Functional effects of GDNF-loaded microparticles implanted into the striatum 
The ultimate proof-of-concept on the potential neurorestorative effect exerted by 
microencapsulated GDNF was evaluated in an animal model of partial dopaminergic 
depletion. The experimental design is summarized in Figure 2.  
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Figure 2: Time course of the experiments. Animals received GDNF-loaded microparticles, non-loaded 
microparticles or microspheres dispersing medium 2 weeks after 6-OHDA lesion. Rotational behavior 
was analyzed before microspheres implantation and at 2, 4, 6 and 8 weeks post-implantation. At this time, 
animals were sacrificed to perform immunohistochemical analysis. 
 
The intraparenchymal delivery of the neurotoxin 6-OHDA resulted in a successful 
partial dopaminergic denervation within the striatum, appropriate to evaluate the 
efficacy of GDNF-loaded microspheres. Amphetamine-induced motor behavior was 
taken as an indicator of the degree of dopaminergic lesion resulting from the 6-OHDA 
delivery. Only rats showing more than 6 turns ipsilateral to the lesion side per minute 
were considered as properly lesioned and then used for microspheres implantation. All 
rats survived the implantation of microspheres, which was well tolerated by the animals. 
Rats were tested with amphetamine 2, 4, 6 and 8 weeks after microparticles 
implantation. The evolution in time of the mean score of amphetamine-induced 
rotations of the animals is shown in Figure 3. No statistically significant differences in 
the number of rotations between groups were observed before microparticle 
implantation. Our data showed that, during the 2 months analyzed, the administration of 
either sham or non-loaded microspheres did not cause any significant change in the 
number of turns ipsilateral to the lesion per minute (Sham from 11.48 ± 1.5 to 11.49 ± 
1.70 and non-loaded microspheres from 10.02 ± 1.4 to 10.75 ± 2.9). By contrast, 
animals treated with GDNF-loaded microspheres showed a gradual reduction in the 
number of ipsilateral turns per minute, from 9.5 ± 0.7 before microparticle implantation 
to 1.5 ± 1 two months post-treatment. The decrease has been noticed 4 weeks after 
microsphere implantation. At this point, the number of turns per minute induced by 
amphetamine was reduced by 28%. Marked differences were more evident 6 weeks 
after treatment, and at this point the scores reached statistical significance when 
compared both to sham and to non loaded-microsphere treated animals (p< 0.05). Two 
months after treatment, the reduction in the number of ipsilateral turns was still 
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maintained achieving a total abolition of amphetamine-induced rotation in GDNF-
treated animals. Interestingly, it was observed that this score was even normalized (0.6, 
0.1 and 0.015 turn per minute) for 3 rats in this group. At this time, the score of GDNF 
microsphere-treated animals was statistically different when compare both to sham and 
to non loaded-microsphere treated animals (p < 0.05) (Figure 3). 
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Figure 3: Changes in the amphetamine-induced rotational behavior after treatment with GDNF-loaded 
microspheres. There is a marked decrease on the number of net turns 4 weeks post-treatment. Rotational 
behavior markedly decreased 6 weeks after GDNF treatment and this recovery was still maintained 8 
weeks post-treatment. The administration of either the microspheres dispersing medium (sham) or empty 
microspheres has no impact on the rotational behavior observed after i.p. injection of 5 mg/Kg of 
amphetamine. Each bar represents the mean value ± S.E. (*p<0.05 compared to the non-loaded 
microparticles treated group and to the animals that received the microparticles dispersing medium) 
 
3.4.2 Histological effects of striatal GDNF microparticle implantation 
Animals were sacrificed 8 weeks after treatment to verify whether the improvement in 
the behavioral test was accomplished by GDNF induced reinnervation of dopaminergic 
fibers in the striatum. Brain sections were stained immunocytochemically for TH, a 
marker for dopaminergic neurons (Figure 4). The striatum of animals treated with 
GDNF-loaded microparticles showed a clear increase in TH-immunostaining (Figure 
4A''), which was especially prominent in the area close to the injection site of the 
particles. The striatal reinnervation was due to the GDNF delivery since this effect was 
not observed in the animal groups treated with the empty microspheres (Figure 4B'') or 
with the dispersing medium (Figure 4C'').  
6-OHDA treated striatumIntact striatum
 
9 
Figure 4: Photomicrographs of striatums immunostained for TH from intact hemispheres (A', B' and C') 
and 6-OHDA lesioned hemispheres injected with GDNF-loaded microspheres (A''), non-loaded 
microspheres (B'') and dispersium medium (C'') 15 days after the partial dopaminergic lesion. The striatal 
reinnervation induced by the 8-week treatment with microencapsulated GDNF was characterized by the 
presence of dense plexus of TH immunoreactive fibers (A”). Such a substantial striatal reinnervation has 
never been noticed in the animal groups treated with empty microspheres (B”) or with the dispersing 
medium (C”). Scale bar is 100 µm. 
 
The increase in TH-immunostaining in animals treated GDNF-loaded microspheres was 
quantified by measuring the OD at rostral, medial and caudal levels of the striatum. OD 
values for the striatum on the ipsilateral side were expressed as a percentage of the 
contralateral non-lesioned side. The density of TH-immunopositive fibers in the 
striatum of sham and non-loaded microspheres was approximately 60% of that in the 
non-lesioned striatum in the three levels analyzed (Figure 5). In the GDNF treated 
animals, the OD was 77.44 ± 8.24%, 91.75 ± 9.69% and 95 ± 5.74% in the rostral, 
medial and caudal sections respectively, which were significantly different (p<0.05) 
when compared to animals treated with non-loaded microspheres and with sham in the 
three levels analyzed. Moreover, when comparing sections of GDNF treated animals, 
quantitative densitometry revealed that the most abundant reinnervation was noticed 
within medial and caudal levels of the striatum, which corresponded to the levels 
located closer to the microparticle injection sites (Figure 5). This probably reflects the 
important diffusion of GDNF from microparticles at these levels.  
 
 
Figure 5: Changes in the optical density (OD) at the three levels of the striatum analyzed, expressed as 
the percentage of lesion versus the control side, as result of the 8-week treatment with microencapsulated 
GDNF. Significant increases in optical density of the TH stain were found in the striatum of animals 
treated with GDNF-loaded microspheres with respect to the other two groups (*p<0.05). This effect was 
observed in the three levels of the striatum analyzed, and was more pronounced in medial and caudal 
striatal levels, the ones more closely located to the injection site. This is probably due to the diffusion of 
GDNF from microparticles at this level. Mean values ± S.E. 
 
Interestingly, non-loaded and GDNF-loaded microparticles were still visible by optical 
microscopy 2 months post-implantation. No evidence of damage was observed on the 
tissue that surrounds the implanted microparticles indicating that they were well 
tolerated. Consistent with previous reports, GFAP-positive reactive astrocytes were 
observed around the needle tract (Figure 6A) [14, 16, 24]. This reaction was the same 
for the 3 groups of animals demonstrating that the astrocytic response is attributed to the 
mechanical trauma that occurs during surgery and not to the polymer. No CD11b 
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positive macrophages were found (Figure 6D). It was noticed that both GDNF-loaded 
microparticles and non-loaded microparticles were not totally degraded at this time.  
 
A B C
D E F
GFAP 
Cd11b MP rod 
MP rod 
Merged 
Merged 
Figure 6: Confocal microscopy images of sections through the striatum 2 months after microparticles 
injection immunostained for GAFP (A) and CD11b (D) in green and adjacent striatal sections showing 
fluorescent rhodamine microparticles in red (B and E). Histological analysis revealed a limited moderate 
astrocytic reaction in A where some astrocytes were stained with GFAP antibody. As can be observed in 
C, which is the merge of A and B, the astrocytic reaction was localized surrounding the microparticles 
injection site. This reaction was the same for the 3 groups of animals. No CD11b positive macrophages 
were found 2 months after microparticles implantation (D). We can note that microparticles were not 
totally degraded 2 months after implantation and that they were uniformly distributed along the injection 
site (B and E). Scale bar represents 20 µm. 
 
Immunohistochemical detection of GDNF 5 weeks post-implantation showed 
immunoreactivity within the GDNF-microparticles injection site (Figure 7 A-A’). As 
shown in Figure 7, GDNF could still be detected 5 weeks following microparticles 
implantation, indicating that microparticles were suitable for long-term GDNF delivery. 
 
3.4.3 Evaluation of serum IgG antibody response against rat glycosylated GDNF  
To assess the systemic safety of rat glycosylated recombinant GDNF administration, 
serum GDNF antibodies levels were measured by ELISA in all the animals. Sera from 
GDNF-MP treated animals were negative for GDNF antibodies. The serum samples 
obtained from non-loaded treated animals and from sham-operated animals were also 
negative for GDNF antibodies.  
 
 
Figure 7: Low power photomicrographs (A, B) and insets (A', B') of striatal sections immunostained for 
GDNF of rats treated with GDNF-loaded microspheres (A-A') and rats treated with non-loaded 
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microspheres (B, B') at 5 weeks after treatment. The immunohistochemistry for GDNF showed the 
deposit of GDNF-loaded microspheres within the striatum (A, A') which is more evident in the inset A'. 
GDNF-immunoreactive microparticles were still visible after five weeks post-injection. Scale bar is 500 
µm in panel A and B, and 100 µm in panel A' and B'.  
 
4. Discussion 
The present paper is a proof-of-concept study, designed to assess the potential 
neurorestorative properties of microencapsulated GDNF within biodegradable and 
biocompatible PLGA microspheres. The trophic effect of GDNF on the dopaminergic 
system is widely acknowledged in the current bibliography [1, 2]. However, the 
potential value of this protein for PD treatment is hindered by several safety and 
efficacy concerns related to the brain delivery strategies attempted so far. In this regard, 
there is an urgent need to develop a safe and effective GDNF brain delivery system, as 
was emphasized in a recent paper where the use of GDNF for PD treatment was 
discussed [25]. An ideal vector or device for GDNF brain delivery must meet several 
criteria, such as, compatibility with the host tissue, no immunological reaction, minimal 
damage at the injection site and controlled release of the protein to the CNS. 
Furthermore, in an attempt to improve the biological activity and to reduce adverse 
effects such as the generation of blocking antibodies against GDNF, the administered 
neurotrophic factor should closely mimic the endogenous protein glycosylation pattern. 
Although none of the existing strategies for GDNF brain delivery fulfill these 
demanding criteria, microencapsulated GDNF within PLGA microspheres comes closer 
to meeting these requirements.  
Jollivet et al. proposed for the first time the brain delivery of GDNF using PLGA 
microspheres in order to induce dopaminergic reinnervation in a partial model of PD 
[26]. Parkinsonian rats treated with microparticles loaded with the nonglycosylated 
protein, experimented functional improvements accompanied with neural regeneration. 
Consequently, it was demonstrated that microparticles were appropriate to deliver the 
neurotrophic factor into the CNS [26, 27]. In this present work, notable modifications 
have been made in order to enhance the effect of microencapsulated GDNF and to 
reduce some safety concerns.  
First, and most significant, was the use of highly purified GDNF with a glycosylation 
pattern similar to the endogenous protein [20]. Thus, injection of impurities to the CNS 
was avoided and production of antibodies against the neurotrophic factor was prevented. 
This aspect is crucial because one of the safety concerns which halted the phase II 
clinical trials in which patients received a protein expressed in E. coli, was the detection 
of antibodies against GDNF in 10% of the patients when the protein was injected 
through an infusion pump [6]. Antibodies could be easily generated against exogenous 
GDNF produced in bacteria, which differs from the endogenous protein in its 
glycosylation pattern [28].  No antibody response to rat GDNF was detected in this 
work, where glycosylated recombinant GDNF had been used.  
The second modification made was improving the preparation method of the 
microparticles. In this present study, particles were prepared by TROMS technology. 
This system that involves the injection of the phases under a turbulent regime is ideal 
for encapsulation of complex and fragile bioactive molecules. Shear forces such as 
ultrasound or high pressure homogenizers are avoided allowing for proteins to remain 
biologically active during the manufacturing process [18]. In the present study, GDNF 
bioactivity was preserved throughout the process as demonstrated by the in vitro 
differentiation of PC-12 cells. These results confirmed TROMS technology as an 
appropriate method for the microencapsulation of fragile therapeutic agents such as 
neurotrophic factors. Furthermore, another significant benefit of this innovative system 
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in view of its industrial application is the consistent production of very homogeneous 
batches of microparticles allowing for an easy scale-up of the manufacturing process.  
Another improvement is the reduction of the microparticle injection volume required for 
implantation into the brain. Our study used 20% less injection volume compared to 
others who used larger volumes for an even distribution of microparticles within the 
tissue [24, 26, 27]. Despite the small volume of injection used, microspheres were 
uniformly distributed along the site of injection (Figure 6 and 7). The volume of 
injection is a crucial safety factor as reduction in injection volume may reduce the 
mechanical trauma, non-specific lesions and animal behavior deficits due to 
microspheres administration. Interestingly, in this work and in contrast to previous 
studies [26], results from amphetamine-induced rotational behavior indicate that 
behavior of experimental animals did not deteriorate over time (Figure 3). 
As a result of these variations, microparticles prepared by TROMS and loaded with 
glycosylated GDNF exhibited excellent in vivo efficacy and safety with a consistent 
improvement in behavior, significantly different from both controls and non-loaded 
microparticles 6 weeks after implantation. Furthermore, 60% of the animals treated with 
GDNF-loaded microparticles fully recovered from their rotational asymmetry 8 weeks 
after treatment and 20% exhibited less than 2 turns per minute at the same time. The 
motor behavior restoration was accompanied with a higher fiber density in the GDNF 
treated striatum, as Jollivet et al previously described [26], making this strategy 
effective for delivering GDNF in the striatum of hemiparkinsonian rats. The data 
presented in this article offers valuable evidence that the enhanced in vivo 
neurorestorative effect observed is likely to be the result of the improvements discussed.  
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